DE69840426D1 - Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron - Google Patents

Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron

Info

Publication number
DE69840426D1
DE69840426D1 DE69840426T DE69840426T DE69840426D1 DE 69840426 D1 DE69840426 D1 DE 69840426D1 DE 69840426 T DE69840426 T DE 69840426T DE 69840426 T DE69840426 T DE 69840426T DE 69840426 D1 DE69840426 D1 DE 69840426D1
Authority
DE
Germany
Prior art keywords
penetration
testosterone
irritation
promoting
reducing systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840426T
Other languages
English (en)
Inventor
Vivien H W Mak
Stephen Grayson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strakan International Ltd Great Britain
Original Assignee
Strakan International Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22059554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69840426(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strakan International Ltd Great Britain filed Critical Strakan International Ltd Great Britain
Application granted granted Critical
Publication of DE69840426D1 publication Critical patent/DE69840426D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69840426T 1997-11-10 1998-11-09 Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron Expired - Lifetime DE69840426D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6498097P 1997-11-10 1997-11-10

Publications (1)

Publication Number Publication Date
DE69840426D1 true DE69840426D1 (de) 2009-02-12

Family

ID=22059554

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840426T Expired - Lifetime DE69840426D1 (de) 1997-11-10 1998-11-09 Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron

Country Status (17)

Country Link
US (3) US6319913B1 (de)
EP (2) EP1030668A4 (de)
JP (2) JP4139860B2 (de)
KR (1) KR100648536B1 (de)
CN (1) CN1172674C (de)
AT (1) ATE418988T1 (de)
AU (1) AU747041B2 (de)
BR (1) BR9814014B1 (de)
CA (1) CA2309688C (de)
DE (1) DE69840426D1 (de)
DK (1) DK1510213T3 (de)
ES (1) ES2318233T3 (de)
IL (1) IL136042A (de)
NO (1) NO20002422L (de)
NZ (1) NZ504423A (de)
PT (1) PT1510213E (de)
WO (1) WO1999024041A1 (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840426D1 (de) * 1997-11-10 2009-02-12 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
CN102327253A (zh) * 2000-04-26 2012-01-25 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP2004507511A (ja) * 2000-08-30 2004-03-11 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 女性におけるテストステロンおよび近縁ステロイド濃度を増大させる方法
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
NZ524601A (en) * 2000-08-30 2006-04-28 Unimed Pharmaceuticals Inc Method for treating erectile dysfunction and increasing libido in men
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
JP5039252B2 (ja) * 2000-08-31 2012-10-03 ユニメッド ファーマシューティカルズ，リミティド ライアビリティ カンパニー 性機能低下を治療するための医薬組成物及び方法
SK7932003A3 (en) * 2000-12-22 2003-11-04 August Wolff Gmbh & Co Dr Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
CA2451839C (en) * 2001-06-22 2013-08-06 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions comprising peptides and permeation enhancers
AU2002333193A1 (en) * 2001-08-15 2003-03-03 Leo Pharma A/S A pharmaceutical composition for dermal application
WO2003028667A2 (en) * 2001-10-04 2003-04-10 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
EP1455697A4 (de) 2001-12-20 2009-08-05 Femmepharma Holding Co Inc Vaginale verabreichung von arzneimitteln
WO2004091631A1 (en) * 2002-03-15 2004-10-28 Unimed Pharmaceuticals, Inc. Androgen pharmaceutical composition and method for treating depression
BR0308584A (pt) * 2002-03-15 2005-02-22 Unimed Pharmaceuticals Inc Composição farmacêutica androgênica e método para tratamento de depressão
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US6959640B2 (en) * 2002-06-06 2005-11-01 Omega Patents, L.L.C. Device for magnetically treating materials and associated methods
JP5160018B2 (ja) 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
US7099713B2 (en) 2002-06-28 2006-08-29 Battelle Memorial Institute Skin conduction and transport systems
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
WO2004060322A2 (en) 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
WO2004075822A2 (fr) * 2003-02-20 2004-09-10 Besins International Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
FR2856926B1 (fr) * 2003-07-02 2005-09-30 Centre Nat Rech Scient Utilisation des n-alkanols comme activateurs du canal cftr
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
NZ546106A (en) 2003-10-10 2008-10-31 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20050244502A1 (en) * 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
EP1634583A1 (de) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterongele enthaltend Propylenglykol als Resorptionsverstärker
EP1802258A4 (de) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchrone transdermale arzneiabgabe
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20070042026A1 (en) * 2005-03-17 2007-02-22 Wille John J Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CN102091079B (zh) 2005-06-03 2014-03-12 艾克若克斯Dds有限公司 用于透皮给药的方法和组合物
GB0518558D0 (en) * 2005-09-12 2005-10-19 Givaudan Sa Improvements in or related to organic compounds
ZA200803087B (en) 2005-10-12 2009-11-25 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008083158A2 (en) * 2006-12-26 2008-07-10 Femmepharma Holding Company, Inc. Topical administration of danazol
BRPI0720945A2 (pt) 2007-01-11 2012-12-25 Acrux Dds Pty Ltd instrumento espalhador
US9283177B2 (en) * 2007-01-16 2016-03-15 Juventio, Llc Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
CA2675797A1 (en) * 2007-01-16 2008-07-24 Dermworx, Incorporated Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2009090558A2 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
EP2278947A4 (de) * 2008-05-21 2013-11-06 Teikoku Pharma Usa Inc Behandlung von dysmenorrhea durch transdermale verabreichung von nichtsteroidalen entzündungshemmenden arzneimitteln
WO2010008600A1 (en) * 2008-07-16 2010-01-21 Dermworx Incorporated Topical drug delivery system
RU2011111206A (ru) * 2008-10-31 2012-12-10 Моберг Дерма Аб Композиции для местного применения, содержащие комбинацию по меньшей мере двух агентов, усиливающих проникновение
SI2373305T1 (sl) * 2008-12-11 2017-09-29 Besins Healthcare Luxembourg Sarl Transdermalni farmacevtski sestavki, ki obsegajo serm
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
EP4249001A3 (de) 2009-08-21 2023-11-29 Novan, Inc. Topische gele
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CA2776474C (en) 2009-10-02 2021-01-12 Foamix Ltd. Topical tetracycline compositions
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
CN102309669B (zh) * 2010-07-08 2013-07-03 高健生 一种治疗变态反应性结膜炎的中药制剂
EP2640398A4 (de) 2010-11-18 2014-05-14 White Mountain Pharma Inc Verfahren zur behandlung chronischer bzw. nicht linderbarer schmerzen und/oder erhöhung der schmerzschwelle bei einem patienten und pharmazeutische zusammensetzung zur verwendung darin
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR20200118228A (ko) * 2011-05-15 2020-10-14 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
EP2729131B1 (de) 2011-07-05 2020-04-15 Novan, Inc. Topische zusammensetzungen
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
CN102335390B (zh) * 2011-09-30 2013-01-02 王巍 一种治疗面部湿疹的洗剂
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US9855211B2 (en) * 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016007834A1 (en) 2014-07-11 2016-01-14 Novan, Inc. Topical antiviral compositions and methods of using the same
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
JP6444956B2 (ja) * 2015-09-30 2018-12-26 富士フイルム株式会社 経皮吸収用組成物
JP7090549B2 (ja) 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド 炎症のための治療用組成物およびその治療方法
CN109310630A (zh) 2016-04-13 2019-02-05 诺万公司 用于治疗感染的组合物、系统、试剂盒和方法
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
EP3758679A4 (de) 2018-03-01 2021-12-15 Novan, Inc. Stickoxidfreisetzende zäpfchen und verfahren zur verwendung davon
EP3801732A4 (de) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Verfahren und systeme zur wirkstofffreisetzung
AU2019365255A1 (en) 2018-10-26 2021-06-03 Viramal Limited Mucoadhesive gel composition
TW202305125A (zh) 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 用於經修飾mhc表現之溶瘤病毒

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US175329A (en) * 1876-03-28 Improvement in processes of preserving burial-cases
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
JPS59134710A (ja) 1983-01-21 1984-08-02 Suntory Ltd 発酵養毛化粧料
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
JPS6067409A (ja) 1983-09-22 1985-04-17 Suntory Ltd 頭髪用化粧料
US4743588A (en) * 1984-06-13 1988-05-10 Allergan Pharmaceuticals, Inc. Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
ATE77559T1 (de) * 1986-11-14 1992-07-15 Theratech Inc Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
CA1331137C (en) * 1988-02-29 1994-08-02 Pfizer, Inc. Transdermal flux enhancing compositions
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
EP0371496A1 (de) * 1988-12-01 1990-06-06 Schering Corporation Arzneizubereitungen zur transdermalen Verabreichung von Östradiol
EP0416173B1 (de) * 1989-08-23 1997-01-15 Hitachi, Ltd. Verfahren zur Richtigstellung von Netzwerkwichtungsfaktoren in einer mehrschichtigen Perceptronvorrichtung und eine solche Vorrichtung mit Mitteln zur Ausführung dieses Verfahrens
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
DE69231536T2 (de) * 1991-08-26 2001-06-13 Abbott Lab Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
KR950701508A (ko) * 1992-06-11 1995-04-28 챨스 디 에버트 경피식 약물수송을 조절하기 위한 글리세린의 용도(the use of glycerin in moderating transdermal drug delivery)
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU2345695A (en) * 1994-04-28 1995-11-29 F. Hoffmann-La Roche Ag Pharmaceutical composition for transdermal delivery
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
AU1429697A (en) * 1995-12-29 1997-07-28 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5760096A (en) 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
BR9712474A (pt) * 1996-10-30 1999-10-26 Theratech Inc •steres de ácido graxo de sais de ácido láctico como melhoradores de permeação
DE69840426D1 (de) * 1997-11-10 2009-02-12 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron
US6465009B1 (en) 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
WO2003028667A2 (en) 2001-10-04 2003-04-10 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment

Also Published As

Publication number Publication date
CA2309688C (en) 2007-04-24
JP2005047932A (ja) 2005-02-24
IL136042A (en) 2005-12-18
EP1510213A3 (de) 2005-03-23
CN1172674C (zh) 2004-10-27
AU1313299A (en) 1999-05-31
ES2318233T3 (es) 2009-05-01
ATE418988T1 (de) 2009-01-15
DK1510213T3 (da) 2009-03-23
KR100648536B1 (ko) 2006-11-24
US20020058650A1 (en) 2002-05-16
EP1510213A2 (de) 2005-03-02
EP1030668A1 (de) 2000-08-30
NZ504423A (en) 2003-04-29
JP2001522804A (ja) 2001-11-20
WO1999024041A1 (en) 1999-05-20
US6319913B1 (en) 2001-11-20
PT1510213E (pt) 2009-02-12
AU747041C (en) 1999-05-31
US7157097B2 (en) 2007-01-02
IL136042A0 (en) 2001-05-20
KR20010031984A (ko) 2001-04-16
EP1030668A4 (de) 2002-09-25
AU747041B2 (en) 2002-05-09
CA2309688A1 (en) 1999-05-20
NO20002422D0 (no) 2000-05-10
NO20002422L (no) 2000-06-21
CN1285749A (zh) 2001-02-28
US20030166625A1 (en) 2003-09-04
US6579865B2 (en) 2003-06-17
BR9814014A (pt) 2000-09-26
EP1510213B1 (de) 2008-12-31
BR9814014B1 (pt) 2014-10-07
JP4139860B2 (ja) 2008-08-27

Similar Documents

Publication Publication Date Title
ATE418988T1 (de) Penetrationsfördernde und irritationsvermindernde systeme mit testosteron
NZ296893A (en) Treatment/prevention of adverse reactions to skin irritants by administration of a loop diuretic optionally in conjunction with a mast cell degranulator or a glucocorticosteroid;transdermal delivery device
GR1002807B (el) Συστημα για την τοπικη θεραπεια της ακμης και μεθοδος παραγωγης του
AU6607898A (en) Transdermal therapeutic system
DK0892638T3 (da) Liposombaseret, topisk vitamin D-præparat
DE59603597D1 (de) Therapeutische zubereitung zur transdermalen applikation von wirkstoffen durch die haut
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
BR0215102A (pt) Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
PT971694E (pt) Preparacoes de medicamentos para o tratamento de disfuncao sexual
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
PT855916E (pt) Composicao farmaceutica contendo um estimulador de activina ou inibina
ES2140575T3 (es) L-lisil-glicil-l-histidina y agente terapeutico para curar heridas que lo contiene.
DK131586A (da) Transdermalt, antiallergisk, farmaceutisk praeparat
NZ228305A (en) Topical preparation comprised of griseofulvin, phenol and resorcinol
BR9914197A (pt) Processo de tratamento da perda de cabelos com o uso de cetoamidas
ZA977895B (en) Transdermal therapeutic system having an active compound combination comprising oestriol.
AU1290797A (en) Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation

Legal Events

Date Code Title Description
8363 Opposition against the patent